Gliosarcoma Pipeline Therapeutics Review H1 2017

1
Gliosarcoma Pipeline Review H1 2017

• Published  June 2017 Single User
  US 2000
• No. of Pages 187 Corporate
  User US 6000

www.ReportsandReports.com
Website
2
Gliosarcoma Pipeline Market Reviews in H1 2017
Report

• Gliosarcoma Pipeline Review H1 2017 provides
  comprehensive information on the therapeutics
  under development for Gliosarcoma (Oncology),
  complete with analysis by stage of development,
  drug target, mechanism of action (MoA), route of
  administration (RoA) and molecule type.
  Gliosarcoma Pipeline guide 2017 covers the
  descriptive pharmacological action of the
  therapeutics, its complete research and
  development history and latest news and press
  releases.
• Inquire for Complete 187 Pages PDF Report at
  http//www.reportsnreports.com/contacts/inquirybef
  orebuy.aspx?name1057904
• The Gliosarcoma (Oncology) pipeline guide also
  reviews of key players involved in therapeutic
  development for Gliosarcoma and features dormant
  and discontinued projects. The guide covers
  therapeutics under Development by Companies
  /Universities /Institutes, the molecules
  developed by Companies in Phase II, Phase I and
  Preclinical stages are 14, 10 and 1 respectively.
  Similarly, the Universities portfolio in Phase I
  stages comprises 1 molecules, respectively.
• Gliosarcoma (Oncology) pipeline guide helps in
  identifying and tracking emerging players in the
  market and their portfolios, enhances decision
  making capabilities and helps to create effective
  counter strategies to gain competitive advantage.
  The guide is built using data and information
  sourced from Global Markets Direct?s proprietary
  databases, company/university websites, clinical
  trial registries, conferences, SEC filings,
  investor presentations and featured press
  releases from company/university sites and
  industry-specific third party sources.
  Additionally, various dynamic tracking processes
  ensure that the most recent developments are
  captured on a real time basis.

3
Gliosarcoma Pipeline Market Reviews in H1 2017
Report

• Companies Involved in Gliosarcoma Therapeutics
  Development Discussed Agenus Inc, Bristol-Myers
  Squibb Company, Celgene Corp, DelMar
  Pharmaceuticals Inc, ERC Belgium SA, Merck Co,
  Merrimack Pharmaceuticals, Millennium
  Pharmaceuticals, NewLink Genetics Corp, Northwest
  Biotherapeutics, Novartis AG, Nuo Therapeutics,
  Progenics Pharmaceuticals, Tragara
  Pharmaceuticals.
• Gliosarcoma Drug Profiles Discussed ALD-451 ,
  alisertib , avadomide hydrochloride , BMS-986016
  , dasatinib , DCVax-L , dianhydrogalactitol ,
  DNX-2401 , ERC-1671 72, flucytosine TBio-01 73,
  G-200 , indoximod, irinotecan hydrochloride ,
  irinotecan hydrochloride TBio-02 , lonafarnib ,
  M-032 , marizomib , p28 , pazopanib hydrochloride
  , pembrolizumab , PSMA ADC , RRX-001 ,
  sapanisertib , SGT-53 , TG-02 , urelumab

Get Discount at http//www.reportsnreports.com/co
ntacts/discount.aspx?name1057904.
4
Gliosarcoma Pipeline Market Reviews in H1 2017
Report

• Scope
• The pipeline guide provides a snapshot of the
  global therapeutic landscape of Gliosarcoma
  (Oncology) and reviews pipeline therapeutics for
  Gliosarcoma (Oncology) by companies and
  universities/research institutes based on
  information derived from company and
  industry-specific sources. This report also
  covers pipeline products based on several stages
  of development ranging from pre-registration till
  discovery and undisclosed stages as well as
  features descriptive drug profiles for the
  pipeline products which comprise product
  description, descriptive licensing and
  collaboration details, RD brief, MoA other
  developmental activities. In this pipeline report
  Key companies involved in Gliosarcoma (Oncology)
  therapeutics and enlist their entire major and
  minor projects are covered. Gliosarcoma
  (Oncology) therapeutics based on mechanism of
  action (MoA), drug target, route of
  administration (RoA) and molecule type are deeply
  described in this report.
• Buy Complete Report at http//www.reportsnreports.
  com/purchase.aspx?name1057904

5
Gliosarcoma Pipeline Market Reviews in H1 2017
Report
List of Tables 1.Number of Products under
Development for Gliosarcoma, H1 2017 2.Number of
Products under Development by Companies, H1
2017 3.Number of Products under Development by
Universities/Institutes, H1 2017 4.Products under
Development by Companies, H1 2017 5.Products
under Development by Companies, H1 2017
(Contd..1), H1 2017 6.Products under Development
by Universities/Institutes, H1 2017 7.Number of
Products by Stage and Target, H1 2017 8.Number of
Products by Stage and Target, H1 2017 (Contd..1),
H1 2017 9.Number of Products by Stage and
Mechanism of Action, H1 2017 10.Number of
Products by Stage and Mechanism of Action, H1
2017 (Contd..1), H1 2017 11.Number of Products by
Stage and Route of Administration, H1
2017 12.Number of Products by Stage and Molecule
Type, H1 2017 13.Gliosarcoma - Pipeline by Agenus
Inc, H1 2017 14.Gliosarcoma - Pipeline by
Bristol-Myers Squibb Company, H1
2017 15.Gliosarcoma - Pipeline by Celgene Corp,
H1 2017 16.Gliosarcoma - Pipeline by DelMar
Pharmaceuticals Inc, H1 2017 17.Gliosarcoma -
Pipeline by ERC Belgium SA, H1 2017 18.Gliosarcoma
- Pipeline by Merck Co Inc, H1 2017
5
6
About Us

• ReportsnReports.com is your single source for all
  market research needs. Our database includes
  500,000 market research reports from over 95
  leading global publishers in-depth market
  research studies of over 5000 micro markets.
• We provide 24/7 online and offline support to our
  customers.
• Tel Phone No 1-888-391-5441 E-mail
  sales_at_reportsnreports.com

www.ReportsandReports.com
Website
www.ReportsandReports.com
Website